Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 30 | 2023 | 3165 | 3.280 |
Why?
|
Kidney Neoplasms | 28 | 2023 | 4251 | 2.800 |
Why?
|
Pelvis | 9 | 2020 | 733 | 1.610 |
Why?
|
Posture | 6 | 2020 | 957 | 1.060 |
Why?
|
Spine | 5 | 2020 | 1118 | 0.960 |
Why?
|
Gait | 4 | 2020 | 814 | 0.840 |
Why?
|
Neoplasms | 22 | 2023 | 22173 | 0.830 |
Why?
|
Cerebral Palsy | 4 | 2018 | 474 | 0.790 |
Why?
|
Immunotherapy | 11 | 2023 | 4652 | 0.730 |
Why?
|
Scoliosis | 4 | 2020 | 741 | 0.670 |
Why?
|
Imaging, Three-Dimensional | 9 | 2020 | 4062 | 0.660 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2022 | 783 | 0.630 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 11742 | 0.610 |
Why?
|
Salvage Therapy | 2 | 2018 | 1263 | 0.580 |
Why?
|
Nephritis, Interstitial | 1 | 2018 | 155 | 0.570 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 13642 | 0.550 |
Why?
|
Kyphosis | 2 | 2020 | 237 | 0.550 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2022 | 2223 | 0.550 |
Why?
|
Walking | 4 | 2020 | 1198 | 0.500 |
Why?
|
Down Syndrome | 3 | 2018 | 901 | 0.500 |
Why?
|
Patient Positioning | 3 | 2018 | 326 | 0.480 |
Why?
|
Purines | 1 | 2018 | 607 | 0.470 |
Why?
|
Bone and Bones | 2 | 2020 | 2568 | 0.460 |
Why?
|
Aminopyridines | 1 | 2018 | 573 | 0.450 |
Why?
|
Physical Fitness | 1 | 2018 | 743 | 0.450 |
Why?
|
Androgen Antagonists | 2 | 2021 | 1410 | 0.410 |
Why?
|
Benzimidazoles | 1 | 2018 | 858 | 0.410 |
Why?
|
Cervical Vertebrae | 2 | 2018 | 980 | 0.400 |
Why?
|
Pandemics | 10 | 2022 | 8656 | 0.370 |
Why?
|
Lordosis | 2 | 2018 | 92 | 0.360 |
Why?
|
Pyridines | 3 | 2020 | 2875 | 0.350 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 320 | 0.350 |
Why?
|
Therapies, Investigational | 1 | 2021 | 111 | 0.340 |
Why?
|
Humans | 93 | 2023 | 761596 | 0.340 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.340 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 318 | 0.330 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 159 | 0.320 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.320 |
Why?
|
Radiography | 6 | 2020 | 6965 | 0.310 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3086 | 0.310 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3206 | 0.310 |
Why?
|
Crohn Disease | 2 | 2019 | 2279 | 0.310 |
Why?
|
Spinal Curvatures | 1 | 2018 | 71 | 0.300 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3201 | 0.300 |
Why?
|
Acetabulum | 2 | 2020 | 542 | 0.290 |
Why?
|
Femur | 2 | 2018 | 1307 | 0.290 |
Why?
|
Immunologic Factors | 3 | 2021 | 1590 | 0.290 |
Why?
|
Thigh | 1 | 2018 | 241 | 0.290 |
Why?
|
Piperazines | 1 | 2018 | 2523 | 0.290 |
Why?
|
Interleukin-8 | 1 | 2020 | 696 | 0.280 |
Why?
|
Fixation, Ocular | 1 | 2018 | 242 | 0.280 |
Why?
|
Foot Deformities | 1 | 2016 | 35 | 0.270 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 857 | 0.270 |
Why?
|
Lebanon | 5 | 2019 | 245 | 0.260 |
Why?
|
Postural Balance | 1 | 2020 | 622 | 0.250 |
Why?
|
Pelvic Bones | 1 | 2017 | 270 | 0.250 |
Why?
|
Spinal Cord Diseases | 1 | 2018 | 292 | 0.250 |
Why?
|
Lower Extremity | 3 | 2020 | 1202 | 0.250 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3358 | 0.250 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2023 | 3492 | 0.240 |
Why?
|
Algorithms | 2 | 2021 | 14033 | 0.240 |
Why?
|
Tomography, Spiral Computed | 1 | 2016 | 273 | 0.240 |
Why?
|
Joints | 1 | 2016 | 322 | 0.240 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2894 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4580 | 0.230 |
Why?
|
Immunoconjugates | 1 | 2022 | 953 | 0.230 |
Why?
|
Gait Disorders, Neurologic | 1 | 2016 | 240 | 0.230 |
Why?
|
Body Mass Index | 3 | 2021 | 12953 | 0.230 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3878 | 0.230 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 597 | 0.220 |
Why?
|
Urban Population | 1 | 2022 | 2036 | 0.220 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1609 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2022 | 8554 | 0.210 |
Why?
|
Infection Control | 1 | 2020 | 982 | 0.210 |
Why?
|
Male | 43 | 2023 | 360846 | 0.210 |
Why?
|
Young Adult | 18 | 2020 | 59260 | 0.210 |
Why?
|
Retreatment | 2 | 2020 | 598 | 0.210 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 1222 | 0.200 |
Why?
|
Joint Diseases | 1 | 2016 | 459 | 0.200 |
Why?
|
Female | 40 | 2023 | 392705 | 0.190 |
Why?
|
Upper Extremity | 1 | 2016 | 658 | 0.190 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1334 | 0.190 |
Why?
|
Prostatic Neoplasms | 3 | 2021 | 11122 | 0.190 |
Why?
|
Rural Population | 1 | 2022 | 2287 | 0.190 |
Why?
|
Nephrectomy | 3 | 2022 | 937 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20568 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9280 | 0.180 |
Why?
|
Anilides | 2 | 2020 | 411 | 0.180 |
Why?
|
Survival Analysis | 4 | 2021 | 10090 | 0.180 |
Why?
|
Aged | 25 | 2023 | 169310 | 0.170 |
Why?
|
Retrospective Studies | 19 | 2023 | 80647 | 0.170 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1588 | 0.170 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8002 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5672 | 0.170 |
Why?
|
Functional Laterality | 1 | 2016 | 2257 | 0.170 |
Why?
|
Middle Aged | 25 | 2023 | 220921 | 0.170 |
Why?
|
Sexual Behavior | 1 | 2019 | 2180 | 0.170 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 26129 | 0.170 |
Why?
|
Movement | 1 | 2016 | 1478 | 0.170 |
Why?
|
Hip Joint | 1 | 2016 | 1014 | 0.160 |
Why?
|
Adult | 24 | 2022 | 221210 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7593 | 0.160 |
Why?
|
Parenteral Nutrition, Total | 1 | 2019 | 304 | 0.150 |
Why?
|
Sarcoma | 1 | 2019 | 1801 | 0.150 |
Why?
|
Outpatients | 1 | 2016 | 1597 | 0.150 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9177 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2472 | 0.140 |
Why?
|
Adolescent | 14 | 2020 | 88326 | 0.140 |
Why?
|
Medical Oncology | 3 | 2022 | 2321 | 0.140 |
Why?
|
Enterobacteriaceae Infections | 1 | 2019 | 188 | 0.140 |
Why?
|
Cohort Studies | 7 | 2023 | 41495 | 0.140 |
Why?
|
Femur Neck | 1 | 2018 | 314 | 0.140 |
Why?
|
Aged, 80 and over | 13 | 2021 | 58984 | 0.140 |
Why?
|
Liver Failure | 1 | 2018 | 250 | 0.130 |
Why?
|
Biomedical Research | 1 | 2022 | 3429 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 4948 | 0.130 |
Why?
|
DNA Methylation | 1 | 2020 | 4399 | 0.130 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8527 | 0.130 |
Why?
|
Carrier State | 1 | 2019 | 523 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 350 | 0.120 |
Why?
|
Multiple Organ Failure | 2 | 2023 | 387 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1742 | 0.120 |
Why?
|
Platelet Count | 1 | 2017 | 781 | 0.120 |
Why?
|
Melanoma | 1 | 2023 | 5709 | 0.120 |
Why?
|
Taxoids | 1 | 2017 | 668 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1188 | 0.110 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 561 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 305 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10212 | 0.110 |
Why?
|
Palliative Care | 2 | 2019 | 3598 | 0.110 |
Why?
|
Anthropometry | 1 | 2018 | 1349 | 0.110 |
Why?
|
Leukocyte Count | 1 | 2017 | 1596 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4420 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1475 | 0.100 |
Why?
|
Renal Insufficiency | 1 | 2018 | 809 | 0.100 |
Why?
|
Computer Simulation | 1 | 2016 | 6241 | 0.100 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5337 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15843 | 0.100 |
Why?
|
Methotrexate | 1 | 2019 | 1719 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2018 | 2425 | 0.100 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1866 | 0.100 |
Why?
|
Tennessee | 1 | 2021 | 120 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1125 | 0.100 |
Why?
|
Health Facilities | 2 | 2022 | 580 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11120 | 0.100 |
Why?
|
Neutrophils | 2 | 2020 | 3767 | 0.090 |
Why?
|
Genomics | 4 | 2022 | 5821 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13381 | 0.090 |
Why?
|
Angiotensin I | 1 | 2021 | 56 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2020 | 20100 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1092 | 0.090 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.090 |
Why?
|
Censuses | 1 | 2022 | 202 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5314 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21019 | 0.090 |
Why?
|
Risk Factors | 6 | 2022 | 74213 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4915 | 0.090 |
Why?
|
Joint Instability | 2 | 2018 | 801 | 0.090 |
Why?
|
Cause of Death | 3 | 2022 | 3683 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1230 | 0.080 |
Why?
|
Reference Values | 2 | 2017 | 4920 | 0.080 |
Why?
|
Indoles | 1 | 2018 | 1833 | 0.080 |
Why?
|
Cell Cycle | 1 | 2018 | 2932 | 0.080 |
Why?
|
Cross Infection | 1 | 2019 | 1422 | 0.080 |
Why?
|
Postoperative Period | 2 | 2019 | 1814 | 0.080 |
Why?
|
Lymphocytes | 1 | 2017 | 2612 | 0.080 |
Why?
|
Pyrimidines | 2 | 2018 | 3028 | 0.080 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 362 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2017 | 22176 | 0.080 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.080 |
Why?
|
Telemedicine | 2 | 2020 | 3052 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6345 | 0.080 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 12723 | 0.080 |
Why?
|
Mutation | 3 | 2021 | 30053 | 0.080 |
Why?
|
Ligases | 1 | 2020 | 333 | 0.080 |
Why?
|
Anatomy, Comparative | 1 | 2017 | 4 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.080 |
Why?
|
Calcaneus | 1 | 2020 | 142 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1866 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1979 | 0.080 |
Why?
|
Angiotensin II | 1 | 2021 | 849 | 0.070 |
Why?
|
Condoms | 1 | 2019 | 331 | 0.070 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.070 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 737 | 0.070 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 455 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2578 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 2510 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9032 | 0.070 |
Why?
|
Syphilis | 1 | 2019 | 243 | 0.070 |
Why?
|
Foot Joints | 1 | 2016 | 35 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2297 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2020 | 64685 | 0.070 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9610 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 426 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 738 | 0.060 |
Why?
|
Foot | 1 | 2020 | 575 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3600 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1062 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6312 | 0.060 |
Why?
|
Students, Medical | 1 | 2019 | 1936 | 0.060 |
Why?
|
Rotation | 1 | 2017 | 517 | 0.060 |
Why?
|
Bone Density | 1 | 2018 | 3551 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1516 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12059 | 0.060 |
Why?
|
DNA Helicases | 1 | 2020 | 851 | 0.060 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1079 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 54423 | 0.060 |
Why?
|
Biopsy | 2 | 2021 | 6766 | 0.060 |
Why?
|
Transcription Factors | 3 | 2021 | 12130 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3639 | 0.060 |
Why?
|
Organ Size | 1 | 2018 | 2254 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12690 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4317 | 0.050 |
Why?
|
HIV Infections | 1 | 2019 | 17354 | 0.050 |
Why?
|
International Cooperation | 1 | 2019 | 1422 | 0.050 |
Why?
|
Colonoscopy | 1 | 2021 | 1394 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29629 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 143 | 0.050 |
Why?
|
Accidental Falls | 1 | 2020 | 1068 | 0.050 |
Why?
|
Child | 5 | 2018 | 80158 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2469 | 0.050 |
Why?
|
Electromyography | 1 | 2016 | 1394 | 0.050 |
Why?
|
Observer Variation | 1 | 2017 | 2606 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2630 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1899 | 0.040 |
Why?
|
Diet | 1 | 2018 | 8075 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2805 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 185 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3514 | 0.040 |
Why?
|
Mammography | 1 | 2021 | 2430 | 0.040 |
Why?
|
Databases, Factual | 2 | 2020 | 7968 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 2928 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 6228 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 9647 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 522 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 367 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 199 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 231 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 231 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
Preceptorship | 1 | 2019 | 56 | 0.040 |
Why?
|
Diaphyses | 1 | 2018 | 65 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 3744 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2021 | 5112 | 0.040 |
Why?
|
Massachusetts | 1 | 2021 | 8833 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 698 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 609 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 323 | 0.040 |
Why?
|
Femur Head | 1 | 2018 | 297 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 304 | 0.030 |
Why?
|
Macrophages | 1 | 2021 | 5767 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11076 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 899 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1435 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2467 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5305 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 682 | 0.030 |
Why?
|
Registries | 1 | 2022 | 8225 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1386 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.030 |
Why?
|
Mass Screening | 1 | 2021 | 5429 | 0.030 |
Why?
|
Quality Improvement | 1 | 2020 | 3802 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5799 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 432 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1003 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2020 | 1251 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1115 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11671 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1702 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3359 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 846 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 39969 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1321 | 0.030 |
Why?
|
Universities | 1 | 2019 | 993 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2020 | 4811 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2021 | 1163 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2665 | 0.030 |
Why?
|
Prevalence | 1 | 2019 | 15733 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2021 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2057 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2161 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2048 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1286 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3384 | 0.020 |
Why?
|
United States | 2 | 2022 | 72340 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39106 | 0.020 |
Why?
|
Animals | 2 | 2021 | 168475 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6484 | 0.020 |
Why?
|
Quality of Life | 1 | 2019 | 13367 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4352 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3060 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6815 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9327 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8466 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3424 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10554 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5293 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10508 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6992 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7828 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7048 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18399 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23996 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23447 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11461 | 0.010 |
Why?
|